• Tianjin TEDA Biomedical Engineering clarified on October 26, 2026, that its 4,000,000-share award grant does not require shareholder approval.
• The recipient’s awards over the 12 months through the grant date represent approximately 0.28% of issued H shares, 0.19% of total shares.
• The grant remains below the 1% shareholder-approval threshold for the recipient, a group employee who is a subsidiary shareholder and director.
• Other information in the October 21, 2026, grant announcement remains unchanged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin TEDA Biomedical Engineering Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261026-12382775), on October 26, 2026, and is solely responsible for the information contained therein.